Sanofi Joins Peers, Will Make Lantus Available At $35 For All US Patients

New Pricing Kicks In 1 January 2024

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Sanofi is the last of three big insulin makers to offer its top-selling insulin at the same out-of-pocket cost regardless of patients’ insurance coverage, but calls for other health care players to make concessions as well.

Percentage down, arrow icon with percent falling down
Sanofi will cut the cost of Lantus by 78% • Source: Shutterstock

Sanofi announced late on 16 March that it will cut the list price of its top-selling insulin Lantus (insulin glargine) by 78% and establish a $35 cap on out-of-pocket costs for all patients with commercial insurance, starting 1 January 2024. The French big pharma joins Eli Lilly and Company and Novo Nordisk A/S, which also announced plans this month that will bring their insulin products more in line with a $35 cap on copays under Medicare Part D, a requirement of last year’s Inflation Reduction Act.

Sanofi said in its statement about the Lantus pricing change and copay cost cap that the company believes “no one...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Drug Pricing

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains